Get the Stockscreener App
8.335
3.54%
0.285
Elicio Therapeutics Inc stock is traded at $8.335, with a volume of 79,008.
It is up +3.54% in the last 24 hours and down -8.91% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$8.05
Open:
$8.03
24h Volume:
79,008
Relative Volume:
0.85
Market Cap:
$143.85M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.3257
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
-9.01%
1M Performance:
-8.91%
6M Performance:
+2.90%
1Y Performance:
+64.72%
1-Day Range:
$7.83
$8.59
1-Week Range:
$7.43
$9.55
52-Week Range:
$4.60
$12.62
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
8.335 | 138.93M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
How Elicio Therapeutics Inc. (9HA) stock reacts to stronger dollarQuarterly Market Summary & Safe Capital Allocation Plans - Newser
How Elicio Therapeutics Inc. (9HA) stock reacts to new regulations2025 Winners & Losers & Long-Term Growth Plans - Newser
Will Elicio Therapeutics Inc. (9HA) stock benefit from mergersTrade Ideas & Risk Controlled Swing Trade Alerts - Newser
Avoiding Lag: Real-Time Signals in (ELTX) Movement - news.stocktradersdaily.com
Can Elicio Therapeutics Inc. stock deliver surprise earnings beat2025 Volatility Report & Real-Time Buy Zone Alerts - Newser
Can Elicio Therapeutics Inc. (9HA) stock sustain margin levelsAnalyst Downgrade & Safe Capital Growth Plans - Newser
Will Elicio Therapeutics Inc. stock benefit from AI adoptionWeekly Stock Recap & Weekly Stock Performance Updates - Newser
How Elicio Therapeutics Inc. (9HA) stock trades in high volatilityWeekly Trade Recap & Weekly Return Optimization Alerts - Newser
Is Elicio Therapeutics Inc. (9HA) stock undervalued historicallyTreasury Yields & Technical Analysis for Trade Confirmation - Newser
Will Elicio Therapeutics Inc. (9HA) stock split increase liquidity2025 Earnings Surprises & Fast Moving Market Watchlists - Newser
How Elicio Therapeutics Inc. (9HA) stock compares with top peers - Newser
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025 - MSN
Discipline and Rules-Based Execution in ELTX Response - news.stocktradersdaily.com
Can Elicio Therapeutics Inc. (9HA) stock sustain breakout momentumQuarterly Market Summary & High Accuracy Swing Entry Alerts - newser.com
Is Elicio Therapeutics Inc. stock a smart buy before Fed meeting2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Why Elicio Therapeutics Inc. (9HA) stock remains stableProfit Target & Consistent Return Investment Signals - newser.com
How Elicio Therapeutics Inc. stock performs in weak economyJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
Can Elicio Therapeutics Inc. stock maintain operating marginsQuarterly Growth Report & Stock Timing and Entry Methods - newser.com
Retail investors are Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) biggest owners and were hit after market cap dropped US$8.5m - simplywall.st
How Elicio Therapeutics Inc. (9HA) stock performs during market turbulenceJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - newser.com
Can Elicio Therapeutics Inc. stock outperform in 2025 bull market2025 Biggest Moves & Free High Accuracy Swing Entry Alerts - newser.com
How high can Elicio Therapeutics Inc. stock goJuly 2025 Fed Impact & High Yield Stock Recommendations - newser.com
Elicio Therapeutics appoints Marc Wolfgang as chief technology officer By Investing.com - Investing.com Nigeria
Elicio Therapeutics Inc. stock trendline breakdownTrade Entry Summary & Low Volatility Stock Suggestions - newser.com
What earnings revisions data tells us about Elicio Therapeutics Inc.Trade Entry Report & Short-Term Trading Opportunity Alerts - newser.com
Elicio Therapeutics, Inc. Appoints Marc J. Wolfgang, M.S. as Chief Technology Officer - MarketScreener
Elicio Therapeutics appoints Marc Wolfgang as chief technology officer - Investing.com India
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer - The Manila Times
Elicio Therapeutics Appoints Veteran CMC and Technical - GlobeNewswire
Will Elicio Therapeutics Inc. outperform the marketPortfolio Risk Summary & Accurate Buy Signal Alerts - newser.com
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):